Cenra Healthcare, the sales and marketing arm of Cenra Inc., has announced the expansion of its long-standing partnership with Dr. Reddy’s Laboratories (Taiwan) Ltd., a subsidiary of the global pharmaceutical company Dr. Reddy’s.

The collaboration aims to further improve access to affordable and clinically valuable treatments for patients in Taiwan.

Since the alliance began in 2020, the two companies have worked closely to introduce a diverse range of high-quality generic drugs and innovative formulations, particularly in the oncology space.

These include chemotherapy agents, hormone therapies, and targeted treatments for prostate cancer, breast cancer, ovarian cancer, and hematological malignancies.

 “We are proud to strengthen our collaboration with Dr. Reddy's, one of the world's leading pharmaceutical companies with strong R and D capabilities," said Lucas Lin, General Manager of Cenra Healthcare.

"With Cenra Healthcare's broad market coverage and strong presence in Taiwan's healthcare landscape, we are well positioned to support our partners in promoting access to essential medicines. This partnership is built not just on product alignment, but on a shared belief in patient-centric care — delivering affordable, high-quality treatment options backed by long-term trust and mutual values."

Cenra Healthcare noted that the expanded partnership aligns with Taiwan’s National Health Insurance Administration (NHIA) policy that promotes the use of generic drugs in cancer treatment, thereby enhancing medicine supply resilience and safeguarding patient access.

Looking ahead, Cenra Healthcare and Dr. Reddy’s plan to broaden their collaboration by introducing additional proven therapies across multiple therapeutic areas.

In addition, Cenra Healthcare is actively engaging with other global pharmaceutical companes to bring more affordable and much-needed medicines to patients in Taiwan. 

Cenra Inc. (formerly China Chemical and Pharmaceutical Co., Ltd.) is a leading healthcare company in Taiwan, with a diversified portfolio spanning human and veterinary medicines, active pharmaceutical ingredients, health supplements, OTC products, personal care items, and elderly care services.

Dr. Reddy’s Laboratories, headquartered in Hyderabad, India, operates in more than 80 countries, with major markets including the U.S., India, Russia and the CIS region, China, Brazil, and Europe. Its offerings include active pharmaceutical ingredients (APIs), generics, biosimilars, OTC products, innovative formulations, and custom pharmaceutical services. Its core therapeutic areas include oncology, cardiovascular, and gastrointestinal treatments.